drugset
drugset / Trial / NCT06224595

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

NCT06224595 ↗

Phase 1 Completed 112 enrolled Chipscreen Biosciences, Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS32582 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.

Timeline

Start
2024-03-28
Primary completion
2024-11-27
Completion
2024-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject CS32582 Unknown 3 mg Oral
Subject CS32582 Unknown 6 mg Oral
Subject CS32582 Unknown 12 mg Oral
Subject CS32582 Unknown 24 mg Oral
Subject CS32582 Unknown 36 mg Oral
Subject CS32582 Unknown 54 mg Oral

Indications

No indication recorded.